Search Result
Results for "
Y2 receptor
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W013093
-
-
-
- HY-101044
-
|
|
P2X Receptor
Na+/Ca2+ Exchanger
|
Neurological Disease
|
|
PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca 2+ exchanger in guinea pig airway smooth muscle .
|
-
-
- HY-13104
-
MRS 2578
Maximum Cited Publications
12 Publications Verification
|
P2Y Receptor
Apoptosis
|
Cardiovascular Disease
|
|
MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors .
|
-
-
- HY-110126
-
|
|
P2Y Receptor
|
Inflammation/Immunology
Cancer
|
|
AR-C118925XX is a selective P2Y2 receptor antagonist. AR-C118925XX inhibits ATP-induced IL-6 production and phosphorylation of p38. AR-C118925XX also inhibits Bleomycin (HY-108345)-induced dermal fibrosis in mice. AR-C118925XX also inhibits ATP-induced tumor growth .
|
-
-
- HY-14450
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
Endocrinology
|
|
JNJ-31020028 is a selective and brain penetrant antagonist of neuropeptide Y Y2 receptor with pIC50 values of 8.07 and 8.22 for human and rat Y2 receptor, respectively. JNJ-31020028 can be used for the research of nervous disease .
|
-
-
- HY-B0606
-
|
INS365
|
P2Y Receptor
|
Inflammation/Immunology
|
|
Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
|
-
-
- HY-110322A
-
PPTN
4 Publications Verification
|
P2Y Receptor
|
Inflammation/Immunology
|
|
PPTN, a chemical probe, is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
|
-
-
- HY-110322
-
|
|
P2Y Receptor
|
Inflammation/Immunology
|
|
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .
|
-
-
- HY-107723
-
-
-
- HY-P10000
-
|
|
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion .
|
-
-
- HY-107372
-
-
-
- HY-107735
-
-
-
- HY-W250153
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
-
-
- HY-P1011
-
-
-
- HY-P1480
-
-
-
- HY-P1021A
-
-
-
- HY-107731
-
-
-
- HY-P11291A
-
|
|
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
NNC0165-1273 (TFA) is the trifluoroacetic acid of NNC0165-1273 (HY-P11291). NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research .
|
-
-
- HY-P1322
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
[D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats .
|
-
![[D-Trp34]-Neuropeptide Y](//file.medchemexpress.com/product_pic/hy-p1322.gif)
-
- HY-101308A
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .
|
-
-
- HY-107372H
-
|
Uridine 5'-triphosphate trisodium salt, 100 mM Solution, PCR Grade
|
Biochemical Assay Reagents
Endogenous Metabolite
DNA/RNA Synthesis
P2Y Receptor
|
Cardiovascular Disease
|
|
UTP (Uridine 5'-triphosphate) trisodium salt, 100 mM Solution, PCR Grade is a solution prepared from uridine triphosphate at a concentration of 100 mM, free of DNase, RNase and phosphatase contamination, suitable for molecular biology research. Uridine triphosphate (HY-107372) is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate activates membrane-bound P2Y2 receptors .
|
-
-
- HY-164090
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
-
-
- HY-108649A
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
MRS2768 tetrasodium salt is a moderately potent and selective P2Y2 receptor agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro .
|
-
-
- HY-P4805
-
-
-
- HY-P1021
-
-
-
- HY-P11043
-
|
|
GLP Receptor
Neuropeptide Y Receptor
Arrestin
|
Metabolic Disease
|
|
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
|
-
-
- HY-110089
-
|
|
P2Y Receptor
|
Inflammation/Immunology
|
|
mrs 4062 (TEA) is a selective P2Y4 receptor agonist with an EC50 of 23 nM. mrs 4062 (TEA) has EC50s of 640 nM and 740 nM for P2Y2 and P2Y6, respectively .
|
-
-
- HY-P2703
-
|
|
Neuropeptide Y Receptor
|
Metabolic Disease
Endocrinology
|
|
Peptide YY (pig) is a 36 amino acid gastrointestinal peptide, can be isolated from porcine duodenum. Peptide YY (pig) decreases appetite and food-intake by activation of the Y2 receptor. Peptide YY (pig) is present mainly in pancreatic endocrine cells with effect on both intestinal motility and the cardiovascular system .
|
-
-
- HY-P1818
-
-
-
- HY-107479
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
(R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y Y2 receptor antagonist, with pIC50 values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y2 receptor, respectively. (R)-JNJ-31020028 shows >100-fold selective versus human Y1, Y4, and Y5 receptors. (R)-JNJ-31020028 has antidepressant like effects .
|
-
-
- HY-W013093R
-
|
UTP trisodium salt (Standard); Uridine 5'-triphosphate trisodium salt (Standard)
|
Reference Standards
Endogenous Metabolite
P2Y Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Uridine triphosphate (trisodium salt) (Standard) is the analytical standard of Uridine triphosphate (trisodium salt). This product is intended for research and analytical applications. Uridine triphosphate (UTP) trisodium salt is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate trisodium salt activates membrane-bound P2Y2 receptors .
|
-
-
- HY-101986C
-
|
AR-H 053591 dihydrochloride
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
BIIE-0246 dihydrochloride (AR-H 053591 dihydrochloride) is a potent and highly selective non-peptide neuropeptide Y (NPY) Y2 receptor antagonist, with an IC50 value of 15 nM .
|
-
-
- HY-101308
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .
|
-
-
- HY-179133
-
|
|
P2Y Receptor
PKA
Raf
MEK
ERK
|
Inflammation/Immunology
|
|
HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC50 of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .
|
-
-
- HY-N9422
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Adenosine 3'-phosphate 5'-phosphosulfate triethylamine, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate triethylamine can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
-
-
- HY-P10148
-
|
Ac-[Leu28,31]-NPY (24-36)
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) is a selective agonist of neuropeptide Y Y2 receptor. N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) attenuates cardiac vagal action in anaesthetised rats .
|
-
![N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36)](//file.medchemexpress.com/product_pic/hy-p10148.gif)
-
- HY-107732
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
JNJ-5207787 is a nonpeptidic, selective and penetrate the blood-brain barrier neuropeptide Y Y2 receptor (Y2) antagonist. JNJ-5207787 inhibits the binding of peptide YY (PYY) with pIC50s of 7.0 and 7.1 for human Y2 receptor and rat Y2 receptor, respectively. JNJ-5207787 is >100-fold selective versus human Y1, Y4, and Y5 receptors .
|
-
-
- HY-118198
-
-
-
- HY-P3676
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Neuropeptide Y (3-36) (porcine) is an agonist of neuropeptide Y (NPY) receptor subtype Y2, and stimulates feeding in rats. Neuropeptide Y (3-36) (porcine) is a highly Y2 selective ligand compared with nselective Y1/Y2 receptor ligand, Neuropeptide Y 1-36 .
|
-
-
- HY-P11291
-
|
|
Neuropeptide Y Receptor
|
Endocrinology
|
|
NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research .
|
-
-
- HY-180406
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
NPY Y2 antagonist 2 is a modulator targeting the neuropeptide Y (NPY) receptor Y2, with pKi values of 6.8 nM and 7.2 nM in human and rat brains, respectively, and demonstrating blood-brain barrier penetration. NPY Y2 antagonist 2 shows selectivity for the Y1 and Y5 receptors. NPY Y2 antagonist 2 blocks the negative feedback regulation mediated by the NPY Y2 receptor, thereby increasing endogenous NPY release and enhancing Y1 receptor activation, resulting in the modulation of central neurotransmitter release. NPY Y2 antagonist 2 exhibits moderate in vivo clearance, high free fraction in rat brain, and a favorable brain/plasma ratio and brain exposure. NPY Y2 antagonist 2 is applicable for research in conditions such as mood disorders, anxiety induced by alcohol withdrawal, and social anxiety associated with nicotine withdrawal .
|
-
-
- HY-P3677
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Neuropeptide Y (2-36) (porcine) is a porcine-derived neuropeptide with 97.14% homology to rat/human origin. Neuropeptide Y (2-36) (porcine) is also a rat neuropeptide receptor agonist, with EC50 values of 1.2, 1.6 and 3.4 nM for receptor of Y5, Y2 and Y1 respectively. Neuropeptide Y (2-36) (porcine) can be used in studies related to obesity and eating disorders .
|
-
-
- HY-P11044
-
|
|
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC50 of 17.3 nM and an IC50 of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .
|
-
-
- HY-132240
-
-
-
- HY-110092
-
|
|
P2Y Receptor
|
Metabolic Disease
|
|
PSB-1114 tetrasodium is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. PSB-1114 tetrasodium displays >50-fold selectivity versus the P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors .
|
-
-
- HY-P1322A
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
[D-Trp34]-Neuropeptide Y TFA is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y TFA is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y TFA markedly increases food intake in rats .
|
-
![[D-Trp34]-Neuropeptide Y TFA](//file.medchemexpress.com/product_pic/hy-p1322a.gif)
-
- HY-P1321A
-
|
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
-
- HY-W250153A
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
-
-
- HY-107735R
-
|
|
Reference Standards
Neuropeptide Y Receptor
|
Neurological Disease
|
|
CYM 9484 (Standard) is the analytical standard of CYM 9484 (HY-107735). This product is intended for research and analytical applications. CYM 9484 is a selective and highly potent neuropeptide Y (NPY) Y2 receptor antagonist with an IC50 value of 19 nM .
|
-
-
- HY-137616C
-
|
|
P2Y Receptor
|
Cancer
|
|
Rp-dUTPαS (tetrasodium) is an isomer of the sulfur-containing nucleoride dUTP-α-S and an agonist of the purinergic P2Y2 receptor. Rp-dUTPαS (tetrasodium) selectively induces inositol phosphate accumulation in P2Y2-expressing 1321N1 cells with an EC50 of 12.5 μM .
|
-
- HY-137606
-
|
UP4A
|
P2X Receptor
|
Cardiovascular Disease
|
|
Uridine adenosine tetraphosphate (UP4A) is an endothelium-derived vasoconstrictor that primarily acts through the P2X1 receptor and possibly through the P2Y2 and P2Y4 receptors. Uridine adenosine tetraphosphate can be used in the study of cardiovascular diseases .
|
-
- HY-137612C
-
|
Rp-Uridine 5'-O-1-thiotriphosphate tetrasodium
|
P2Y Receptor
|
Cancer
|
|
Rp-UTP-α-S (Rp-Uridine 5'-O-(1-thiotriphosphate)) tetrasodium is a nucleotide agonist of purinergic P2Y2 and P2Y4 receptors. Rp-UTP-α-S (tetrasodium) can induce inositol phosphate accumulation in P2Y2 or P2Y4 expressing 1321N1 cells with EC50 values of 5.4 and 27 μM .
|
-
- HY-108651
-
|
UTPγS trisodium
|
P2Y Receptor
|
Metabolic Disease
|
|
Uridine-5'-O-(3-thiotriphosphate) trisodium, a stable analogue of UTP, is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability .
|
-
- HY-137612
-
|
Uridine 5'-O-1-thiotriphosphate
|
P2Y Receptor
|
Cancer
|
|
Sp-UTP-α-S (Uridine 5-0-1-thiotrirhosphate) is a P2Y2 and P2Y4 receptor activator. Sp-UTP-α-S can be used in cancer research .
|
-
- HY-110092A
-
|
|
P2Y Receptor
|
Cancer
|
|
PSB-1114 triethylamine is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. PSB-1114 triethylamine displays >50-fold selectivity versus the P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors .
|
-
- HY-134369
-
|
|
P2Y Receptor
|
Others
Inflammation/Immunology
|
|
Ap4C tetrasodium is a dinucleoside polyphosphate containing purine and pyrimidine base moieties. Ap4C tetrasodium acts as a signaling molecule by binding to specific P2Y receptors, activating P2Y2 and P2Y4 receptors in platelets, leading to platelet aggregation and other cellular responses. Ap4C tetrasodium can be used for research in inflammation and blood coagulation .
|
-
- HY-13104R
-
|
|
P2Y Receptor
Apoptosis
|
Cardiovascular Disease
|
|
MRS 2578 (Standard) is the analytical standard of MRS 2578. This product is intended for research and analytical applications. MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors .
|
-
- HY-103055
-
|
|
P2Y Receptor
|
Inflammation/Immunology
|
|
PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
|
-
- HY-175251
-
|
|
GABA Receptor
|
Neurological Disease
|
|
GABAA receptor modulator-9 is and positive allosteric modulator of a1β2y2 subtype GABAA that can cross the blood-brain barrier. GABAA receptor modulator-9 exhibits comparable activity on α1β2γ2 (EC50: 0.9 μM in oocytes, 0.2 μM in CHO cells) and on α1β2, α3β2γ2 and α1β3γ2 (EC50s of 1.3, 3.4 and 1.1 μM). GABAA receptor modulator-9 significantly suppresses seizure progression and reduces delayed mortality. GABAA receptor modulator-9 can be used for the study of status epilepticus (SE) .
|
-
- HY-137603
-
|
UTPγS
|
P2Y Receptor
|
Metabolic Disease
|
|
Uridine-5'-O-(3-thiotriphosphate) (UTPγS), a stable analogue of Uridine triphosphate (UTP) (HY-107372), is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability. Uridine-5'-O-(3-thiotriphosphate) stimulates inositol phosphate formation in human 1321N1 astrocytoma cells stably expressing the phospholipase C-coupled human P2U-purinoceptor (EC50 = 240 nM) .
|
-
- HY-P11275
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes .
|
-
- HY-137612A
-
|
Uridine 5'-O-1-thiotriphosphate tetrasodium
|
P2Y Receptor
|
Cancer
|
|
Sp-UTP-α-S (Uridine 5-0-1-thiotrirhosphate) tetrasodium is a P2Y2 and P2Y4 receptor activator. Sp-UTP-α-S tetrasodium can be used in cancer research .
|
-
- HY-137603A
-
|
UTPγS tetrasodium
|
P2Y Receptor
|
Neurological Disease
Metabolic Disease
|
|
Uridine-5'-O-(3-thiotriphosphate) (UTPγS) tetrasodium, a stable analogue of Uridine triphosphate (UTP) (HY-107372), is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability. Uridine-5'-O-(3-thiotriphosphate) tetrasodium stimulates inositol phosphate formation in human 1321N1 astrocytoma cells stably expressing the phospholipase C-coupled human P2U-purinoceptor (EC50 = 240 nM) .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W250153
-
|
|
Biochemical Assay Reagents
|
|
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
-
- HY-107372H
-
|
Uridine 5'-triphosphate trisodium salt, 100 mM Solution, PCR Grade
|
Biochemical Assay Reagents
|
|
UTP (Uridine 5'-triphosphate) trisodium salt, 100 mM Solution, PCR Grade is a solution prepared from uridine triphosphate at a concentration of 100 mM, free of DNase, RNase and phosphatase contamination, suitable for molecular biology research. Uridine triphosphate (HY-107372) is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate activates membrane-bound P2Y2 receptors .
|
-
- HY-W250153A
-
|
|
Biochemical Assay Reagents
|
|
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10000
-
|
|
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion .
|
-
- HY-P1011
-
-
- HY-P1480
-
-
- HY-P1021A
-
-
- HY-P11291A
-
|
|
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
NNC0165-1273 (TFA) is the trifluoroacetic acid of NNC0165-1273 (HY-P11291). NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research .
|
-
- HY-P1322
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
[D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats .
|
-
- HY-P4805
-
-
- HY-P1021
-
-
- HY-P11043
-
|
|
GLP Receptor
Neuropeptide Y Receptor
Arrestin
|
Metabolic Disease
|
|
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
|
-
- HY-P2703
-
|
|
Neuropeptide Y Receptor
|
Metabolic Disease
Endocrinology
|
|
Peptide YY (pig) is a 36 amino acid gastrointestinal peptide, can be isolated from porcine duodenum. Peptide YY (pig) decreases appetite and food-intake by activation of the Y2 receptor. Peptide YY (pig) is present mainly in pancreatic endocrine cells with effect on both intestinal motility and the cardiovascular system .
|
-
- HY-P1818
-
-
- HY-P10148
-
|
Ac-[Leu28,31]-NPY (24-36)
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) is a selective agonist of neuropeptide Y Y2 receptor. N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36) attenuates cardiac vagal action in anaesthetised rats .
|
-
- HY-P3676
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Neuropeptide Y (3-36) (porcine) is an agonist of neuropeptide Y (NPY) receptor subtype Y2, and stimulates feeding in rats. Neuropeptide Y (3-36) (porcine) is a highly Y2 selective ligand compared with nselective Y1/Y2 receptor ligand, Neuropeptide Y 1-36 .
|
-
- HY-P11291
-
|
|
Neuropeptide Y Receptor
|
Endocrinology
|
|
NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research .
|
-
- HY-P3677
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Neuropeptide Y (2-36) (porcine) is a porcine-derived neuropeptide with 97.14% homology to rat/human origin. Neuropeptide Y (2-36) (porcine) is also a rat neuropeptide receptor agonist, with EC50 values of 1.2, 1.6 and 3.4 nM for receptor of Y5, Y2 and Y1 respectively. Neuropeptide Y (2-36) (porcine) can be used in studies related to obesity and eating disorders .
|
-
- HY-P11044
-
|
|
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC50 of 17.3 nM and an IC50 of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss .
|
-
- HY-P1322A
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
[D-Trp34]-Neuropeptide Y TFA is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y TFA is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y TFA markedly increases food intake in rats .
|
-
- HY-P1321A
-
|
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
- HY-P11275
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Image |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W013093
-
|
UTP trisodium salt; Uridine 5'-triphosphate trisodium salt
|
|
Nucleotide Analogs
|
|
Uridine triphosphate (UTP) trisodium salt is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate trisodium salt activates membrane-bound P2Y2 receptors .
|
-
- HY-107372
-
|
UTP; Uridine 5'-triphosphate
|
|
Nucleotide Analogs
|
|
Uridine triphosphate (UTP; Uridine 5'-triphosphate) is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate activates membrane-bound P2Y2 receptors .
|
-
- HY-W250153
-
|
|
|
Nucleotide Analogs
Adenine Nucleotide
|
|
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
-
- HY-164090
-
|
|
|
Nucleotide Analogs
Adenine Nucleotide
|
|
Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
-
- HY-W250153A
-
|
|
|
Nucleotide Analogs
Adenine Nucleotide
|
|
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca 2+ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[D-Trp34]-Neuropeptide Y](http://file.medchemexpress.com/product_pic/hy-p1322.gif)
![N-Acetyl [Leu28, Leu31] neuropeptide Y (24–36)](http://file.medchemexpress.com/product_pic/hy-p10148.gif)
![[D-Trp34]-Neuropeptide Y TFA](http://file.medchemexpress.com/product_pic/hy-p1322a.gif)
